Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancer

Tomoyoshi Takenaka, Mitsuhiro Takenoyama, Masafumi Yamaguchi, Ryo Toyozawa, Eiko Inamasu, Miyako Kojo, Gouji Toyokawa, Tsukihisa Yoshida, Yoshimasa Shiraishi, Yosuke Morodomi, Fumihiko Hirai, Kenichi Taguchi, Mototsugu Shimokawa, Takashi Seto, Yukito Ichinose

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

OBJECTIVES: The impact of epidermal growth factor receptor (EGFR) status and the use of EGFR-tyrosine kinase inhibitor (EGFR-TKI) therapy have not been well discussed only in recurrent non-small-cell lung cancer (NSCLC). The purpose of this study was to identify the prognostic factors associated with post-recurrence survival after surgical resection of NSCLC in terms of the EGFR mutation status and the use of EGFR-TKI therapy. METHODS: From 2000 through 2011, 1237 consecutive patients with NSCLC underwent pulmonary resection at our institution. Of these patients, 280 experienced postoperative recurrence by the end of 2012. We reviewed the cases of recurrence and analysed the predictors and length of post-recurrence survival. RESULTS: The median post-recurrence survival time and the 5-year survival rate of all patients were 25 months and 20.8%, respectively. A multivariate analysis identified the Eastern Cooperative Oncology Group (ECOG) performance status (PS), brain metastasis, number of sites of recurrence and EGFR mutation status to be independent prognostic factors for post-recurrence survival. Among all cases, the median post-recurrence survival time according to the use of EGFR-TKI therapy was as follows: 49 months in the EGFR mutation-positive patients treated with EGFR-TKI therapy, 20 months in the EGFR wild or unknown cases treated with EGFR-TKI therapy and 17 months in the patients not treated with EGFR-TKI therapy. As to EGFR mutation-positive cases, the patients treated with EGFR-TKIs exhibited significantly longer post-recurrence survival time than the patients treated without EGFR-TKIs (49 vs 12 months). CONCLUSIONS: It is essential for recurrent NSCLC patients to be examined for the EGFR mutation status. Patients with a positive EGFR mutation status receive significant benefits from EGFR-TKI therapy.

Original languageEnglish
Article numberezu227
Pages (from-to)550-555
Number of pages6
JournalEuropean Journal of Cardio-thoracic Surgery
Volume47
Issue number3
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Recurrence
Mutation
Survival
Therapeutics
Protein-Tyrosine Kinases

All Science Journal Classification (ASJC) codes

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancer. / Takenaka, Tomoyoshi; Takenoyama, Mitsuhiro; Yamaguchi, Masafumi; Toyozawa, Ryo; Inamasu, Eiko; Kojo, Miyako; Toyokawa, Gouji; Yoshida, Tsukihisa; Shiraishi, Yoshimasa; Morodomi, Yosuke; Hirai, Fumihiko; Taguchi, Kenichi; Shimokawa, Mototsugu; Seto, Takashi; Ichinose, Yukito.

In: European Journal of Cardio-thoracic Surgery, Vol. 47, No. 3, ezu227, 01.01.2015, p. 550-555.

Research output: Contribution to journalArticle

Takenaka, T, Takenoyama, M, Yamaguchi, M, Toyozawa, R, Inamasu, E, Kojo, M, Toyokawa, G, Yoshida, T, Shiraishi, Y, Morodomi, Y, Hirai, F, Taguchi, K, Shimokawa, M, Seto, T & Ichinose, Y 2015, 'Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancer', European Journal of Cardio-thoracic Surgery, vol. 47, no. 3, ezu227, pp. 550-555. https://doi.org/10.1093/ejcts/ezu227
Takenaka, Tomoyoshi ; Takenoyama, Mitsuhiro ; Yamaguchi, Masafumi ; Toyozawa, Ryo ; Inamasu, Eiko ; Kojo, Miyako ; Toyokawa, Gouji ; Yoshida, Tsukihisa ; Shiraishi, Yoshimasa ; Morodomi, Yosuke ; Hirai, Fumihiko ; Taguchi, Kenichi ; Shimokawa, Mototsugu ; Seto, Takashi ; Ichinose, Yukito. / Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancer. In: European Journal of Cardio-thoracic Surgery. 2015 ; Vol. 47, No. 3. pp. 550-555.
@article{ee315f1bd4134f309be4a570aa6f2e20,
title = "Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancer",
abstract = "OBJECTIVES: The impact of epidermal growth factor receptor (EGFR) status and the use of EGFR-tyrosine kinase inhibitor (EGFR-TKI) therapy have not been well discussed only in recurrent non-small-cell lung cancer (NSCLC). The purpose of this study was to identify the prognostic factors associated with post-recurrence survival after surgical resection of NSCLC in terms of the EGFR mutation status and the use of EGFR-TKI therapy. METHODS: From 2000 through 2011, 1237 consecutive patients with NSCLC underwent pulmonary resection at our institution. Of these patients, 280 experienced postoperative recurrence by the end of 2012. We reviewed the cases of recurrence and analysed the predictors and length of post-recurrence survival. RESULTS: The median post-recurrence survival time and the 5-year survival rate of all patients were 25 months and 20.8{\%}, respectively. A multivariate analysis identified the Eastern Cooperative Oncology Group (ECOG) performance status (PS), brain metastasis, number of sites of recurrence and EGFR mutation status to be independent prognostic factors for post-recurrence survival. Among all cases, the median post-recurrence survival time according to the use of EGFR-TKI therapy was as follows: 49 months in the EGFR mutation-positive patients treated with EGFR-TKI therapy, 20 months in the EGFR wild or unknown cases treated with EGFR-TKI therapy and 17 months in the patients not treated with EGFR-TKI therapy. As to EGFR mutation-positive cases, the patients treated with EGFR-TKIs exhibited significantly longer post-recurrence survival time than the patients treated without EGFR-TKIs (49 vs 12 months). CONCLUSIONS: It is essential for recurrent NSCLC patients to be examined for the EGFR mutation status. Patients with a positive EGFR mutation status receive significant benefits from EGFR-TKI therapy.",
author = "Tomoyoshi Takenaka and Mitsuhiro Takenoyama and Masafumi Yamaguchi and Ryo Toyozawa and Eiko Inamasu and Miyako Kojo and Gouji Toyokawa and Tsukihisa Yoshida and Yoshimasa Shiraishi and Yosuke Morodomi and Fumihiko Hirai and Kenichi Taguchi and Mototsugu Shimokawa and Takashi Seto and Yukito Ichinose",
year = "2015",
month = "1",
day = "1",
doi = "10.1093/ejcts/ezu227",
language = "English",
volume = "47",
pages = "550--555",
journal = "European Journal of Cardio-thoracic Surgery",
issn = "1010-7940",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancer

AU - Takenaka, Tomoyoshi

AU - Takenoyama, Mitsuhiro

AU - Yamaguchi, Masafumi

AU - Toyozawa, Ryo

AU - Inamasu, Eiko

AU - Kojo, Miyako

AU - Toyokawa, Gouji

AU - Yoshida, Tsukihisa

AU - Shiraishi, Yoshimasa

AU - Morodomi, Yosuke

AU - Hirai, Fumihiko

AU - Taguchi, Kenichi

AU - Shimokawa, Mototsugu

AU - Seto, Takashi

AU - Ichinose, Yukito

PY - 2015/1/1

Y1 - 2015/1/1

N2 - OBJECTIVES: The impact of epidermal growth factor receptor (EGFR) status and the use of EGFR-tyrosine kinase inhibitor (EGFR-TKI) therapy have not been well discussed only in recurrent non-small-cell lung cancer (NSCLC). The purpose of this study was to identify the prognostic factors associated with post-recurrence survival after surgical resection of NSCLC in terms of the EGFR mutation status and the use of EGFR-TKI therapy. METHODS: From 2000 through 2011, 1237 consecutive patients with NSCLC underwent pulmonary resection at our institution. Of these patients, 280 experienced postoperative recurrence by the end of 2012. We reviewed the cases of recurrence and analysed the predictors and length of post-recurrence survival. RESULTS: The median post-recurrence survival time and the 5-year survival rate of all patients were 25 months and 20.8%, respectively. A multivariate analysis identified the Eastern Cooperative Oncology Group (ECOG) performance status (PS), brain metastasis, number of sites of recurrence and EGFR mutation status to be independent prognostic factors for post-recurrence survival. Among all cases, the median post-recurrence survival time according to the use of EGFR-TKI therapy was as follows: 49 months in the EGFR mutation-positive patients treated with EGFR-TKI therapy, 20 months in the EGFR wild or unknown cases treated with EGFR-TKI therapy and 17 months in the patients not treated with EGFR-TKI therapy. As to EGFR mutation-positive cases, the patients treated with EGFR-TKIs exhibited significantly longer post-recurrence survival time than the patients treated without EGFR-TKIs (49 vs 12 months). CONCLUSIONS: It is essential for recurrent NSCLC patients to be examined for the EGFR mutation status. Patients with a positive EGFR mutation status receive significant benefits from EGFR-TKI therapy.

AB - OBJECTIVES: The impact of epidermal growth factor receptor (EGFR) status and the use of EGFR-tyrosine kinase inhibitor (EGFR-TKI) therapy have not been well discussed only in recurrent non-small-cell lung cancer (NSCLC). The purpose of this study was to identify the prognostic factors associated with post-recurrence survival after surgical resection of NSCLC in terms of the EGFR mutation status and the use of EGFR-TKI therapy. METHODS: From 2000 through 2011, 1237 consecutive patients with NSCLC underwent pulmonary resection at our institution. Of these patients, 280 experienced postoperative recurrence by the end of 2012. We reviewed the cases of recurrence and analysed the predictors and length of post-recurrence survival. RESULTS: The median post-recurrence survival time and the 5-year survival rate of all patients were 25 months and 20.8%, respectively. A multivariate analysis identified the Eastern Cooperative Oncology Group (ECOG) performance status (PS), brain metastasis, number of sites of recurrence and EGFR mutation status to be independent prognostic factors for post-recurrence survival. Among all cases, the median post-recurrence survival time according to the use of EGFR-TKI therapy was as follows: 49 months in the EGFR mutation-positive patients treated with EGFR-TKI therapy, 20 months in the EGFR wild or unknown cases treated with EGFR-TKI therapy and 17 months in the patients not treated with EGFR-TKI therapy. As to EGFR mutation-positive cases, the patients treated with EGFR-TKIs exhibited significantly longer post-recurrence survival time than the patients treated without EGFR-TKIs (49 vs 12 months). CONCLUSIONS: It is essential for recurrent NSCLC patients to be examined for the EGFR mutation status. Patients with a positive EGFR mutation status receive significant benefits from EGFR-TKI therapy.

UR - http://www.scopus.com/inward/record.url?scp=84928198061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928198061&partnerID=8YFLogxK

U2 - 10.1093/ejcts/ezu227

DO - 10.1093/ejcts/ezu227

M3 - Article

VL - 47

SP - 550

EP - 555

JO - European Journal of Cardio-thoracic Surgery

JF - European Journal of Cardio-thoracic Surgery

SN - 1010-7940

IS - 3

M1 - ezu227

ER -